Page last updated: 2024-12-08

tenulin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

tenulin: toxic constituent of Helenium amarum (bitter sneezeweed); structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
Heleniumgenus[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]
Helenium amarumspecies[no description available]AsteraceaeA large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH]

Cross-References

ID SourceID
PubMed CID227830
CHEMBL ID490324
CHEBI ID9441
MeSH IDM0057174

Synonyms (25)

Synonym
ambros-2-en-12-oic acid, 6-beta,13-epoxy-8-alpha,13-dihydroxy-11-methyl-4-oxo-, gamma-lactone
NCI60_001654
55780-22-8
2h-1,f]azulene-3,9-dione, 2a,4a,5,6,6a,9a,9b,9c-octahydro-2-hydroxy-2,2a,6,9a-tetramethyl-
2h-1,f]azulene-3,9-dione, 2a,4a,5,6,6a,9a,9b,9c-octahydro-2-hydroxy-2,2a,6,9a-tetramethyl-, [2r-(2.alpha.,2a.alpha.,4a.alpha.,6.alpha.,6a.alpha.,9a.beta.,9b.alpha.,9c.alpha.)]-
nsc-19942
nsc19942 ,
(2ar,4as,6r,6ar,9ar,9br,9cr)-2-hydroxy-2,2a,6,9a-tetramethyl-2a,4a,5,6,6a,9a,9b,9c-octahydro-2h-1,4-dioxadicyclopenta[cd,f]azulene-3,9-dione
C09557
tenulin
bdbm50250368
(2ar,4as,6r,6ar,9ar,9br,9cr)-2-hydroxy-2,2a,6,9a-tetramethyl-2a,4a,5,6,6a,9a,9b,9c-octahydro-2h-1,4-dioxadicyclopenta(cd,f)azulene-3,9-dione
chebi:9441 ,
CHEMBL490324 ,
nsc 19942
2h-1,4-dioxadicyclopenta(cd,f)azulene-3,9-dione, 2a,4a,5,6,6a,9a,9b,9c-octahydro-2-hydroxy-2,2a,6,9a-tetramethyl-, (2ar,4as,6r,6ar,9ar,9br,9cr)-
unii-8o6qe3mhr3
8o6qe3mhr3 ,
ambros-2-en-12-oic acid, 6.beta.,13-epoxy-8.alpha.,13-dihydroxy-11-methyl-4-oxo-, .gamma.-lactone
Q27108396
(1r,2r,6r,7r,9s,12r,15r)-13-hydroxy-2,7,12,13-tetramethyl-10,14-dioxatetracyclo[7.5.1.02,6.012,15]pentadec-4-ene-3,11-dione
2-hydroxy-2,2a,6,9a-tetramethyl-2a,4a,5,6,6a,9a,9b,9c-octahydro-2h-1,4-dioxadicyclopenta[cd,f]azulene-3,9-dione
DTXSID60971161
CS-0637568
HY-N10919

Research Excerpts

Actions

ExcerptReferenceRelevance
"Tenulin did not produce lethal DNA damage in any of the strains tested."( DNA damaging effects of three sesquiterpene lactones in repair-deficient mutants of Bacillus subtilis.
Donnelly, KC; Jones, DH; Kim, HL, 1981
)
0.98

Treatment

ExcerptReferenceRelevance
"The tenulin treated mice exhibited the lowest values (46-80% of pretrial control values) at 3.0 hr post-treatment in all tissues except in the stomach, which reached its lowest value at 1.0 hr."( Depletion and resynthesis of tissue thiols by helenalin and tenulin.
Anderson, AC; Kim, HL, 1986
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sesquiterpene lactoneAny member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 2Homo sapiens (human)IC50 (µMol)18.00000.00010.995010.0000AID403340
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (59)

Processvia Protein(s)Taxonomy
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID1149588Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as [methyl-14C]thymidine incorporation to DNA at 0.25 mg/day administered from day 5 to day 7 measured on day 8 by scintillation counting analysis relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149601Antitumor activity against mouse EAC cells assessed as tissue SH stimulation at 0.6 mg measured on day 8 by Ellman method relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149600Antitumor activity against mouse EAC cells assessed as nuclear DNA polymerase activity at 0.6 mg measured on day 8 relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149575Binding affinity to DNA (unknown origin) at 0.015 ug at pH 7.2 after 24 hrs by UV-spectrophotometry1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149586Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as chromatin protein content at 0.25 mg/day administered from day 5 to day 7 measured on day 8 relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149584Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as DNA content at 0.25 mg/day administered from day 5 to day 7 measured on day 8 by UV-spectrophotometry relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149594Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as [gamma-32P] incorporation into histone at 0.25 mg/day administered from day 5 to day 7 measured on day 8 relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID403340Inhibition of COX22005Journal of natural products, Jul, Volume: 68, Issue:7
Expanding the ChemGPS chemical space with natural products.
AID1149592Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as free lysosomal DNAse activity at 0.25 mg/day administered from day 5 to day 7 measured on day 8 relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149590Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as nuclear DNA polymerase activity at 0.25 mg/day administered from day 5 to day 7 measured on day 8 relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149572Binding affinity to dGTP (unknown origin) at 0.015 ug at pH 7.2 after 24 hrs by UV-spectrophotometry1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149603Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as cell viability at 0.25 mg/day administered from day 5 to day 7 measured on day 8 by trypan blue assay relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149597Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as 3',5' cAMP level at 0.25 mg/day administered from day 5 to day 7 measured on day 8 by RIA relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149569Antitumor activity against mouse P388 cells allografted in DBA/2 mouse at 25 mg/kg/day, ip relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149570Cytotoxicity against human Hep2 cells1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149573Binding affinity to dAMP (unknown origin) at 0.015 ug by UV-spectrophotometry1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149567Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as tumor growth inhibition at 33.3 mg/kg/day, ip after 7 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID320961Inhibition of serotonin release in bovine platelets2008Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5
Neural networks as valuable tools to differentiate between sesquiterpene lactones' inhibitory activity on serotonin release and on NF-kappaB.
AID1149574Binding affinity to dATP (unknown origin) at 0.015 ug by UV-spectrophotometry1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149599Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as ascitocrit count per mililitre of fluid at 0.25 mg/day administered from day 5 to day 7 measured on day 8 by hemocytometry relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149566Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as survival at 33.3 mg/kg/day, ip after 7 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149571Binding affinity to dGMP (unknown origin) at 0.015 ug at pH 7.2 after 24 hrs by UV-spectrophotometry1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID1149568Antitumor activity against rat Walker 256 cells allografted in Sprague-Dawley rat at 2.5 mg/kg/day, ip relative to control1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (69.23)18.7374
1990's0 (0.00)18.2507
2000's3 (23.08)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.44 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]